Table 1.
Baseline characteristics.
| Study (ref.) | Sample size (T/C) | Man/woman | Age (years) (mean ± SD) (T/C) | T | C | Outcomes |
|---|---|---|---|---|---|---|
| Huang 2018 [14] | 42/41 | 27/14 | 61.97 ± 3.12 | Febuxostat | Placebo | ①③④⑤ |
| Sircar 2015 [15] | 45/48 | 66/27 | 56.22 ± 9.83/61.83 ± 12.00 | Febuxostat | Placebo | ②⑤ |
| Zhang 2021 (1) [16] | 36/30 | 41/25 | 80.13 ± 9.67 | Febuxostat | Placebo | ①②③④⑤ |
| Zhao 2021 [17] | 41/41 | 47/35 | 68.45 ± 5.20/68.56 ± 5.29 | Febuxostat | Placebo | ①③④⑤ |
| Sezai 2015 [18] | 56/53 | 85/24 | 69.4 ± 10.0/69.1 ± 9.2 | Febuxostat | Allopurinol | ② |
| Tanaka 2015 [19] | 21/19 | 35/5 | 70.1 ± 9.5/66.1 ± 7.0 | Febuxostat | Allopurinol | ② |
| Zhang 2021 (2) [20] | 27/27 | 31/23 | 51.58 ± 1.45/51.56 ± 1.44 | Febuxostat | Allopurinol | ①③④⑤ |
| Zhu 2018 [21] | 32/32 | NA | NA | Febuxostat | Allopurinol | ①③④⑤ |
| Zhang 2021 (3) [22] | 67/67 | 66/68 | 55.1 ± 9.4/54.2 ± 8.4 | Febuxostat | Allopurinol | ①②③④⑤ |
| Wang 2022 [23] | 69/69 | 96/42 | 81.35 ± 2.52/81.40 ± 2.49 | Febuxostat | Allopurinol | ①②④⑤ |
①: serum uric acid; ②: EGFR; ③: serum creatinine; ④: serum urea nitrogen; ⑤: adverse reactions.